Human collagen, type I, alpha 1 (COL1A1) ELISA kit

Code CSB-E13445h
Size 96T,5×96T,10×96T
Price Request a Quote or Start an on-line Chat
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now

Product Details

Target Name
collagen, type I, alpha 1
Alternative Names
Alpha 1 type I collagen ELISA Kit; Alpha 2 type I collagen ELISA Kit; alpha 2 type I procollagen ELISA Kit; alpha 2(I) procollagen ELISA Kit; alpha 2(I)-collagen ELISA Kit; Alpha-1 type I collagen ELISA Kit; alpha1(I) procollagen ELISA Kit; CO1A1_HUMAN ELISA Kit; COL1A1 ELISA Kit; COL1A2 ELISA Kit; collagen alpha 1 chain type I ELISA Kit; Collagen alpha-1(I) chain ELISA Kit; collagen alpha-1(I) chain preproprotein ELISA Kit; Collagen I alpha 1 polypeptide ELISA Kit; Collagen I alpha 2 polypeptide ELISA Kit; collagen of skin; tendon and bone; alpha-1 chain ELISA Kit; collagen of skin; tendon and bone; alpha-2 chain ELISA Kit; Collagen type I alpha 1 ELISA Kit; Collagen type I alpha 2 ELISA Kit; EDSC ELISA Kit; OI1 ELISA Kit; OI2 ELISA Kit; OI3 ELISA Kit; OI4 ELISA Kit; pro-alpha-1 collagen type 1 ELISA Kit; type I proalpha 1 ELISA Kit; type I procollagen alpha 1 chain ELISA Kit; Type I procollagen ELISA Kit
Uniprot No.
Homo sapiens (Human)
Sample Types
serum, plasma, cell culture supernates, tissue homogenates
Detection Range
0.625 ng/mL-40 ng/mL
0.156 ng/mL
Assay Time
Sample Volume
Detection Wavelength
450 nm
Research Area
Signal Transduction
Assay Principle
Intra-assay Precision (Precision within an assay): CV%<8%      
Three samples of known concentration were tested twenty times on one plate to assess.  
Inter-assay Precision (Precision between assays): CV%<10%      
Three samples of known concentration were tested in twenty assays to assess.    
To assess the linearity of the assay, samples were spiked with high concentrations of human COL1A1 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
  Sample Serum(n=4)  
1:1 Average % 86  
Range % 80-101  
1:2 Average % 96  
Range % 91-100  
1:4 Average % 92  
Range % 85-98  
1:8 Average % 90  
Range % 85-100  
The recovery of human COL1A1 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample Type Average % Recovery Range  
Serum (n=5) 89 82-98  
EDTA plasma (n=4) 99 90-110  
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
ng/ml OD1 OD2 Average Corrected  
40 2.543 2.560 2.552 2.364  
20 2.032 2.103 2.068 1.880  
10 1.554 1.600 1.577 1.389  
5 1.173 1.186 1.180 0.992  
2.5 0.618 0.670 0.644 0.456  
1.25 0.425 0.430 0.428 0.240  
0.625 0.298 0.310 0.304 0.116  
0 0.181 0.195 0.188    
Materials provided
  • A micro ELISA plate --- The 96-well plate has been pre-coated with an anti-human COL1A1 antibody. This dismountable microplate can be divided into 12 x 8 strip plates.
  • Two vials lyophilized standard ---Dilute a bottle of the standard at dilution series, read the OD values, and then draw a standard curve.
  • One vial Biotin-labeled COL1A1 antibody (100 x concentrate) (120 μl/bottle) ---Act as the detection antibody.
  • One vial HRP-avidin (100 x concentrate) (120 μl/bottle) ---Bind to the detection antibody and react with the TMB substrate to make the solution chromogenic.
  • One vial Biotin-antibodyDiluent (15 ml/bottle) ---Dilute the Biotin-antibody.
  • One vial HRP-avidin Diluent (15 ml/bottle) ---Dilute the HRP-avidin solution.
  • One vial Sample Diluent (50 ml/bottle)---Dilute the sample to an appropriate concentration.
  • One vial Wash Buffer (25 x concentrate) (20 ml/bottle) ---Wash away unbound or free substances.
  • One vial TMB Substrate (10 ml/bottle) ---Act as the chromogenic agent. TMB interacts with HRP, eliciting the solution turns blue.
  • One vial Stop Solution (10 ml/bottle) ---Stop the color reaction. The solution color immediately turns from blue to yellow.
  • Four Adhesive Strips (For 96 wells) --- Cover the microplate when incubation.
  • An instruction manual
Materials not provided
  • A microplate reader capable of measuring absorbance at 450 nm, with the correction wavelength set at 540 nm or 570 nm.
  • An incubator can provide stable incubation conditions up to 37°C±5°C.
  • Centrifuge
  • Vortex
  • Squirt bottle, manifold dispenser, or automated microplate washer
  • Absorbent paper for blotting the microtiter plate
  • 50-300ul multi-channel micropipette
  • Pipette tips
  • Single-channel micropipette with different ranges
  • 100ml and 500ml graduated cylinders
  • Deionized or distilled water
  • Timer
  • Test tubes for dilution
and FAQs
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx

This Human COL1A1 ELISA Kit was designed for the quantitative measurement of Human COL1A1 protein in serum, plasma, cell culture supernates, tissue homogenates. It is a Sandwich ELISA kit, its detection range is 0.625 ng/mL-40 ng/mL and the sensitivity is 0.156 ng/mL .


Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here


I am interested in this human collagen type I kit CSB-E13445h. I want to ask, it is a whole plate or 8 strips?


The CSB-E13445h 96T kit is 8 wells*12 strips, and the strips can be removed and stored for future use.

Target Background

(From Uniprot)
Type I collagen is a member of group I collagen (fibrillar forming collagen).
Gene References into Functions
  1. results strengthen the evidence for the association between polymorphisms of -1997 G/T, +1245 G/T of the COL1A1 gene in the genetic etiology of keloid scars PMID: 27511505
  2. Structural basis of homo- and heterotrimerization of COL1A1/ COL1A2 has been reported. PMID: 28281531
  3. patients with OI have homogenously thinner corneas compared with controls, we observed that a collagen I chain mutation was not responsible for corneal curvature alterations in OI. PMID: 30272615
  4. Our findings demonstrate that collagen I could enhance the aggressive progression of residual hepatocellular carcinoma cells after suboptimal heat treatment and sorafenib may be a treatment approach to thwart this process. PMID: 30227844
  5. Cellular expression of COL1A1 could promote breast cancer metastasis. COL1A1 is a new prognostic biomarker and a potential therapeutic target for breast cancer, especially in ER+ patients. PMID: 29906404
  6. miR-129-5p level was decreased in fibrotic liver of human, and reduced by rOPN treatment. In contrast, miR-129-5p was induced in HSCs transfected by OPN siRNA. These data suggested that OPN induces Col 1 expression via suppression of miR-129-5p in hepatic stellate cells. PMID: 29196165
  7. Depletion of MRTF-A abolished the upregulation of COL1A1 in response to the TGF-beta or Wnt signaling. PMID: 29807221
  8. Mutations in the COL1A1 and COL1A2 genes associated with osteogenesis imperfecta (OI) types I or III. PMID: 29543922
  9. DNMT1 was downregulated in the Lung Cancer group and its expression was further reduced in the presence of increasing malignant burden as indicated by the endobronchial findings further suggesting an Lung Cancer-specific signature. PMID: 29568927
  10. our results indicated that COL1A1 promotes tumor metastasis, and that its inhibition may suppress CRC cell migration. In addition, the role of COL1A1 in CRC metastasis seems to be associated with the regulation of the WNT/PCP pathway. PMID: 29393423
  11. miR378b represses the mRNA expression levels of COL1A1 via interference with SIRT6 in human dermal fibroblasts. PMID: 28983623
  12. Exogenous proline stimulates type I collagen and HIF-1alpha expression and the process is attenuated by glutamine in human skin fibroblasts. PMID: 28526934
  13. the efficacy of pamidronate treatment does not seem to be related to the genotype of type I collagen in patients with osteogenesis imperfecta. PMID: 28528406
  14. High urine collagen is associated with renal dysfunction in lupus nephritis. PMID: 28339802
  15. MiR-133a-3p could inhibit the proliferation and migration of oral squamous cell carcinoma cells through directly targeting COL1A1 and reducing its expression. PMID: 28569392
  16. COL1A1 gene mutation is associated with osteogenesis imperfecta. PMID: 28810924
  17. Elevation of serum alpha1(I) collagen DNA levels in scleroderma patients may be useful as the diagnostic marker, reflecting the presence of vasculopathy. PMID: 28370352
  18. study showed that GG homozygotes were underrepresented in the ACL-rupture group compared with the control group, which suggests an association with reduced risk of anterior cruciate ligament injury PMID: 27632864
  19. Review/Meta-analysis: possible relationship between GG genotype of COL1A1 +1245G/T polymorphism and osteoporosis risk in post-menopausal women. PMID: 28261929
  20. These results support an activation mechanism of DDR1 whereby collagen induces lateral association of DDR1 dimers and phosphorylation between dimers. PMID: 28590245
  21. This study identified collagen gene sets related to self-reported depression scores in healthy participants. PMID: 28334615
  22. an endoplasmic reticulum complex of resident chaperones that includes HSP47, FKBP65, and BiP regulating the activity of LH2. PMID: 28177155
  23. Although serum procollagen type-1 N-terminal propeptide (PINP) levels were not found to be different, tartrate-resistant acid phosphatase type 5b isoform (TRACP 5b) levels were significantly higher in the control group. PMID: 27840329
  24. mutations of the COL1A1 and COL1A2 genes probably underlie the disease in the four families PMID: 28981938
  25. Our results indicated that COL1A1 rs1800012 polymorphism may be associated with the reduced risk of sports-related tendon or ligament injuries, especially in ACL injuries, and that rare TT may played as a protective role. PMID: 28206959
  26. Significance was detected for GG homozygous carriers (P=0.043); this genotype might be a risk factor for this type of low-density lesion (odds ratio 1.643, 95% confidence interval 1.016-2.658). PMID: 27371342
  27. Breast cancer cells alter the dynamics of stromal fibronectin-collagen interactions. PMID: 27503584
  28. COL1a1 crystal structure of fibronectin type III domain shows an immunoglobulin-like fold containing a beta-sandwich structure, which is formed by a three-stranded beta-sheet. PMID: 29199991
  29. Alterations in the extracellular matrix microenvironment, particularly type I collagen, likely contributes to bladder cancer progression. PMID: 27655672
  30. Strong correlations between the expression of type I, II, IV collagen and osteopontin and the clinical stage of tympanosclerosis indicate the involvement of these proteins in excessive fibrosis and pathological remodeling of the tympanic membrane. PMID: 29068597
  31. The results support the association of COL1A1 gene polymorphisms with fracture and with low BMD at the hip in Mexican population PMID: 26423565
  32. urinary N-telopeptide measured in early postmenopause is most strongly associated with rates of bone loss across the menopause transition. PMID: 27322414
  33. Abnormal regulation of COL1 and COL3 may contribute to the early predisposition to POP in premenopausal women. PMID: 27636223
  34. Genetic variation in COL1A1 and COL1A2 associated with osteogenesis imperfect in Vietnamese patients. PMID: 27519266
  35. 2 patients with osteogenesis imperfecta (father and daughter) had a previously undescribed c.3607C>T (p.Gln1203*) change in the COL1A1 gene. PMID: 27178384
  36. In the patient diagnosed with PCG and retinal detachment, analysis of WES data identified compound heterozygous variants in COL1A1 (p.Met264Leu; p.Ala1083Thr). PMID: 27484908
  37. These data, together with those available in literature, suggest that vascular events are not a diagnostic handle to differentiate patients with the p.(Arg312Cys) COL1A1 mutation from those with COL5A1 and COL5A2 defects, and highlight that during the diagnostic process the presence of at least the p.(Arg312Cys) substitution in COL1A1 should be investigated in cEDS patients without type V collagen mutations. PMID: 28102596
  38. we report an infant with severe OI born following a twin pregnancy in whom the bone disease is caused by a heterozygous pathogenic mutation, c.4160C >T, p.(Ala1387Val) located in the C-propeptide region of COL1A1. Our case adds to the growing evidence of the literature on mutations in the C-propeptide region being associated with a severe OI phenotype. PMID: 27549894
  39. We conducted a retrospective analysis of data from clinical, laboratory, and radiographic information from children evaluated for child abuse in which molecular testing for COL1A1 and COL1A2 genes was conducted. A total of 43 patients underwent molecular testing for Osteogenesis imperfecta (OI) PMID: 27090748
  40. our data revealed that COL1A1, UCP2, and PRPF40A are novel players implicated in the complex network of hypoxia response in non-small cell lung cancer PMID: 28258342
  41. In the individuals with a COL1A1 mutation, 70% (7/10) of those with a glycine substitution located C-terminal of p.Gly305 exhibited DGI in both dentitions while no individual (0/7) with a mutation N-terminal of this point exhibited DGI in either dentition PMID: 28498836
  42. Large COPII vesicles are transport carriers of intracellular carriers of procollagen I. PMID: 28428367
  43. we established a new regulatory model of COL1A1 regulation by HIF-1, and bring out its relationship with Sp3 transcription factor. In a fundamental level, these findings give insights in the mechanisms controlling COL1A1 gene expression. PMID: 27521280
  44. UBQLN4, APP, CTNNB1, SHBG, and COL1A1 might be involved in the development of nonalcoholic fatty liver disease, and are proposed as the potential markers for predicting the development of this condition PMID: 28796060
  45. The levels of the bone formation marker PICP in premenopausal rheumatoid arthritis women were significantly higher than in healthy premenopausal controls. There was a highly significant difference between postmenopausal patients with RA and control pre- and postmenopausal women. Furthermore, postmenopausal RA women had significantly higher plasma PICP concentrations than premenopausal women with RA PMID: 27775453
  46. Depletion of FKBP65 and inhibition of FKBP65 activity reduced the dimeric (active) form of LH2 but did not affect the binding of monomeric (inactive) LH2 to procollagen Ialpha1. PMID: 27298363
  47. This is the first study to quantitatively relate pressure-induced microstructural changes in resistance arteries to the mechanics of their wall. Principal findings using a pig model system were confirmed in human arteries. The combined methods provide a strong tool for future hypothesis-driven studies of microvascular pathologies. PMID: 28432057
  48. COL11A1 as a highly specific biomarker of activated cancer-associated fibroblasts in epithelial cancers. PMID: 27609069
  49. miR-29b can reduce collagen biosynthesis during skin wound healing likely via post-transcriptional inhibition of HSP47 expression. PMID: 27477081
  50. The study shows that circCOL3A1-859267 RNA regulate type I collagen expression in photoaged human dermal fibroblasts, suggesting it may be a novel target for interfering with photoaging. PMID: 28286269

Show More

Hide All

Involvement in disease
Caffey disease (CAFFD); Ehlers-Danlos syndrome, classic type (EDS); Ehlers-Danlos syndrome 7A (EDS7A); Osteogenesis imperfecta 1 (OI1); Osteogenesis imperfecta 2 (OI2); Osteogenesis imperfecta 3 (OI3); Osteogenesis imperfecta 4 (OI4); Osteoporosis (OSTEOP)
Subcellular Location
Secreted, extracellular space, extracellular matrix.
Protein Families
Fibrillar collagen family
Tissue Specificity
Forms the fibrils of tendon, ligaments and bones. In bones the fibrils are mineralized with calcium hydroxyapatite.
Database Links

HGNC: 2197

OMIM: 114000

KEGG: hsa:1277

STRING: 9606.ENSP00000225964

UniGene: Hs.172928

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1